Document is current
Any future updates will be listed below
-
Authors
Krossa, Imène
Pisibon, Céline
Cheli, Yann https://orcid.org/0000-0001-9839-4332
Bille, Karine
Dalmasso, Mélanie
Hamadat, Sabah
Husser, Chrystel
Irondelle, Marie
Cherfils-Vicini, Julien https://orcid.org/0000-0001-7813-1527
Soysouvanh, Frédéric
Nahon-Esteve, Sacha
Martel, Arnaud
Lassalle, Sandra
Caujolle, Jean-Pierre
Maschi, Célia
Baillif, Stéphanie
Hasson, Dan
Carcamo, Saul
Aplin, Andrew E. https://orcid.org/0000-0002-2734-3244
Davidson, Irwin
Bernstein, Emily https://orcid.org/0000-0001-6533-8326
Naim, Valeria https://orcid.org/0000-0002-2149-8712
Ballotti, Robert
Bertolotto, Corine
Strub, Thomas https://orcid.org/0000-0001-6252-0181
-
Funding
Funding for this research was provided by:
Fondation pour la Recherche Médicale (FRM ARF201809006989)
Fondation de France (00120250/WB-2021-33281)
Fondation ARC pour la Recherche sur le Cancer (PJA 20191209328)
Ligue Contre le Cancer
Région Provence-Alpes-Côte d’Azur “Emplois jeunes doctorants”
Melanoma Research Alliance
La Ligue contre le cancer CD94/Val de Marne
French government, INSERM INCA PLBio
- License Information
-
More Information
Article History
Received: 28 April 2025
Revised: 16 July 2025
Accepted: 15 September 2025
First Online: 24 October 2025
Competing interests
: AE Aplin has ownership interest in patent number 9880150 and has a pending patent, PCT/US22/76492. The other authors declare no conflicts of interest.
: Animal experiments were performed in accordance with French law and approved by a local institutional ethical committee.
